or Try an Advanced Search...

    Technical Analysis for ASND - Ascendis Pharma A/S

    Grade Last Price % Change Price Change
    B 94.95 0.94% 0.88
    ASND closed up 0.94 percent on Thursday, September 28, 2023, on 71 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Flat Down
    Historical ASND trend table...
    Date Alert Name Type % Chg
    Bullish Engulfing Bullish 0.00%
    Crossed Above 50 DMA Bullish 0.00%
    Hammer Candlestick Bullish 0.00%
    Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
    Lower Bollinger Band Touch Weakness 0.00%
    50 DMA Resistance Bearish 0.94%
    MACD Bearish Centerline Cross Bearish 0.94%
    Fell Below 50 DMA Bearish 0.79%
    Inside Day Range Contraction 0.79%
    50 DMA Support Bullish -0.58%
    Older End-of-Day Signals for ASND ...

       Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

    Alert Time
    50 DMA Support about 9 hours ago
    Rose Above 50 DMA about 9 hours ago
    Lower Bollinger Band Support about 11 hours ago
    60 Minute Opening Range Breakdown about 12 hours ago
    Fell Below Lower Bollinger Band about 12 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    ASND Chart by TradingView
    Basic chart:

    Profile

    Ascendis Pharma A/S Description

    Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies to treat unmet medical needs. It is developing TransCon human growth hormone that has completed Phase II clinical trials in adults to treat growth hormone deficiency (GHD) and other indications, as well as in Phase II studies in children for treating GHD; and TransCon Treprostinil for the treatment of pulmonary arterial hypertension, a life-threatening disease characterized by elevated blood pressure in the pulmonary arteries. The company is also developing TransCon Insulin for the treatment of diabetes; and TransCon Ranibizumab, a compound to support ranibizumab injection. It has strategic collaborations with Sanofi, Genentech, and United Therapeutics Corporation. The company was founded in 2006 and is headquartered in Hellerup, Denmark.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Life Sciences Disease Diabetes Hypertension Insulin Hormones Pulmonary Arterial Hypertension Breakthrough Therapy Peptide Hormones Drug Therapies Growth Hormone Treatment Of Diabetes Growth Hormone Deficiency Recombinant Proteins Growth Hormone Therapy Prodrug Treprostinil

    Is ASND a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Sep 23 Ascendis Pharma Presents Results from Long-Term enliGHten Trial of TransCon™ hGH in Pediatric Growth Hormone Deficiency
    Sep 22 Here’s What Caused the Volatility in Ascendis Pharma A/S (ASND)
    Sep 15 EMA advisors recommend many new meds at latest meeting
    Sep 15 Ascendis Pharma Launches SKYTROFA® (lonapegsomatropin) in Germany for the Once-Weekly Treatment of Children and Adolescents with Growth Hormone Deficiency
    Sep 15 Ascendis Pharma A/S (ASND) Soars 3.2%: Is Further Upside Left in the Stock?
    Sep 14 Ascendis wins EU backing for hormone replacement therapy
    Sep 14 Ascendis Pharma Receives Positive CHMP Opinion for TransCon™ PTH (palopegteriparatide) for Adults with Chronic Hypoparathyroidism
    Sep 12 Ascendis Pharma: Revenue Promise Meets Cash Flow Challenge
    Sep 10 Analysts Are Betting On Ascendis Pharma A/S (NASDAQ:ASND) With A Big Upgrade This Week
    Sep 6 Is Ascendis Pharma A/S (ASND) Too Good to Be True? A Comprehensive Analysis of a Potential ...
    See more ASND news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 134.48
    52 Week Low 64.33
    Average Volume 283,175
    200-Day Moving Average 99.81
    50-Day Moving Average 94.91
    20-Day Moving Average 98.73
    10-Day Moving Average 96.76
    Average True Range 3.63
    RSI (14) 45.65
    ADX 18.85
    +DI 14.99
    -DI 27.12
    Chandelier Exit (Long, 3 ATRs) 95.57
    Chandelier Exit (Short, 3 ATRs) 102.47
    Upper Bollinger Bands 105.33
    Lower Bollinger Band 92.13
    Percent B (%b) 0.21
    BandWidth 13.37
    MACD Line -0.25
    MACD Signal Line 0.73
    MACD Histogram -0.9858
    Fundamentals Value
    Market Cap 5.07 Billion
    Num Shares 53.4 Million
    EPS -5.09
    Price-to-Earnings (P/E) Ratio -18.64
    Price-to-Sales 753.04
    Price-to-Book 7.67
    PEG Ratio -0.27
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 100.13
    Resistance 3 (R3) 99.59 97.31 99.27
    Resistance 2 (R2) 97.31 95.99 97.59 98.98
    Resistance 1 (R1) 96.13 95.18 96.72 96.68 98.69
    Pivot Point 93.86 93.86 94.15 94.13 93.86
    Support 1 (S1) 92.68 92.54 93.27 93.22 91.21
    Support 2 (S2) 90.40 91.72 90.68 90.92
    Support 3 (S3) 89.22 90.40 90.63
    Support 4 (S4) 89.77